Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EIS-12656 in advanced solid tumors
NCT06525298Phase 2Recruiting
- Sponsor
- Eisbach Bio
- Start
- Sep 2024
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of EIS-12656 in solid tumor (advanced stage) (4 arms), sponsored by Eisbach Bio. Primary endpoints: Treatment-emergent adverse events up to 7 months and Dose limiting toxicity at 21 days. Started Sep 2024; status: recruiting.
02
Drugs
EIS-12656
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06525298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06525298.